Skip to content
    WuXi AppTec logo

    WuXi AppTec

    Shanghai, ChinaFounded 2000
    www.wuxiapptec.comLinkedIn
    Biotech & Life SciencesHealthcare

    WuXi AppTec is a global pharmaceutical CRDMO (Contract Research, Development, and Manufacturing Organization) headquartered in Shanghai that also operates a corporate venture arm, WuXi Healthcare Ventures, investing the parent company's capital in early-stage life sciences and healthcare startups across the U.S. and China. Its venture arm's second fund (WuXi Healthcare Ventures II, L.P.) closed at $290 million in December 2015, targeting cross-border Series A and B investments in therapeutics, diagnostics, and platform technologies.

    50% of their portfolio is in Biotech & Life Sciences. They made 1 investments in the last 12 months. Their most common stage is series-b (44% of deals). Average disclosed round size is $66.1M (across 15 rounds with reported amounts).

    Find people at WuXi AppTec on Goldilocks AI

    Portfolio

    16

    Fund Size

    $290M

    Top Stage

    Series B

    Last 12 Mo

    1

    Team

    Feng Zhang

    Feng Zhang

    Senior Vice President, API Manufacturing

    Florence Shi

    Florence Shi

    Senior Vice President, Chief Financial Officer

    Yu Lu

    Yu Lu

    Senior Vice President, WuXi TIDES, WuXi Chemistry Business Operations

    Zhaohui Zhang

    Zhaohui Zhang

    Executive Vice President, China Chief Operating Officer

    LL

    Lennart Lee

    Managing Director

    Portfolio Breakdown

    Stage Distribution

    Sector Distribution

    Investment Activity

    DealsAvg Round Size

    Portfolio

    18 investments
    CompanyRoundAmountDate
    D3 Bio logoD3 BioSeries C—Dec 2025
    CCutiaIpo$59MJan 2023
    XW Pharma logoXW PharmaSeries C$40MSep 2020
    XXWPharmaSeries C$40MJan 2020
    XXW LaboratoriesSeries C$58MJan 2020
    Arrakis logoArrakisSeries B$75MJan 2019
    AAntengene CorporationSeries B$120MJan 2019
    Fog Pharmaceuticals logoFog PharmaceuticalsSeries B$66MMay 2018
    CStone Pharmaceuticals logoCStone PharmaceuticalsSeries B$260MMay 2018
    RRefuge BiotechnologiesSeries B$25MMay 2018
    IDEAYA Biosciences logoIDEAYA BiosciencesSeries B$94MMar 2018
    LifeMine Therapeutics logoLifeMine TherapeuticsSeries A$55MSep 2017
    Vivace Therapeutics logoVivace TherapeuticsSeries B$25MJun 2017
    AAntengene CorporationSeries A$21MJan 2017
    IDEAYA Biosciences logoIDEAYA BiosciencesSeries A$46MMay 2016
    23andMe logo23andMeSeries E—Oct 2015
    Avelas Biosciences logoAvelas BiosciencesSeries B$6.8MJan 2014
    IIMPACT TherapeuticsSeries A—Jan 2014

    Top Co-Investors

    GV5 shared
    HongShan4 shared
    Boyu Capital4 shared
    Canaan Partners4 shared
    Alexandria Venture Investments3 shared
    Dimension3 shared
    Celgene3 shared
    Panacea Venture3 shared
    WI Harper Group3 shared
    KTB Network3 shared
    ARCH Venture Partners2 shared
    Blue Pool Capital2 shared
    Nextech Invest Ltd.2 shared
    AMD Ventures2 shared
    Fidelity Investments2 shared
    Yunfeng Capital2 shared
    Temasek Holdings (Private) Limited1 shared
    MCI Capital1 shared
    IDG Capital1 shared
    Medicxi1 shared

    Last updated: 8 September 2026